期刊文献+

对乙酰氨基酚诱导的大鼠胆酸盐蓄积性肝损伤机制研究(英文) 被引量:3

Acetaminophen-induced hepatotoxicity in rats is correlated with the accumulation of bile acids: an underlying mechanism
原文传递
导出
摘要 通过测定血浆和肝组织中胆酸盐(BAs)含量的变化及肝组织中转运体表达水平的变化,初步探究对乙酰氨基酚(APAP)致大鼠的肝损伤的机制。SD大鼠42只,随机分为6-h对照组、APAP 6-h组、12-h对照组、APAP 12-h组、24-h对照组和APAP 24-h组。运用LC-MS/MS测定血浆和肝组织中BAs含量;Western blotting评价Bsep、Mrp2、Mrp4、Ntcp和Oatp2表达水平。APAP 6-h组,与6-h对照组相比,血浆和肝组织中BAs含量及肝组织中转运蛋白的表达水平无显著差异。APAP 12-h组,与12-h对照组比较,血浆中BAs含量明显降低(P<0.05),肝组织中BAs含量明显升高(P<0.05);Bsep和Mrp2表达水平显著降低(P<0.05)。APAP 24-h组,与24-h对照组比较,血浆和肝组织中BAs含量均明显升高(P<0.05);Mrp4和Oatp2表达水平显着降低(P<0.05)。APAP诱导的大鼠肝损伤机制可能与其在不同时间抑制Bsep,Mrp2,Mrp4和Oatp2表达水平导致BAs蓄积有关。 In the present study, we aimed to investigate the underlying mechanism of acetaminophen(APAP)-induced hepatotoxicity by measuring the expression levels of liver transporters and concentrations of bile acids(BAs) in rat plasma and liver. SD rats(42) were randomly assigned into six groups, including 6-h control group, APAP 6-h group, 12-h control group, APAP 12-h group, 24-h control group and APAP 24-h group. The estimation study of BAs in plasma and liver was performed on LC-MS/MS. The levels of bile salt export pump(Bsep), multidrug resistant protein 2(Mrp2), multidrug resistant protein 4(Mrp4), Na+/taurocholate cotransporting polypeptide(Ntcp) and organic anion transporting polypeptide 2(Oatp2) in the liver were analyzed by Western blotting analysis. Compared with the corresponding control groups, no difference was found in the BA levels and the expressions of BA transporters in the plasma and liver after 6 h of APAP administration. While BA levels were significantly decreased in the plasma and increased in the liver after 12 h of APAP administration(P0.05); and the expressions of Bsep and Mrp2 were significantly reduced(P0.05). After 24 h of APAP administration, BA levels were both greatly increased in the plasma and liver(P0.05); and the expressions of Mrp4 and Oatp2 were significantly decreased(P0.05). In response to over-dose APAP, Bsep, Mrp2, Mrp4 and Oatp2 levels were reduced at different time points, causing the accumulation of BAs, and such accumulation may ultimately lead to the severe liver injury, which could be an underlying mechanism of the APAP-induced hepatotoxicity.
作者 靳永文 饶志 武艳芳 张国强 石阿茜 魏玉辉 武新安 Yongwen Jin;Zhi Rao;Yanfang WU;Guoqiang Zhang;Axi Shi;Yuhui Wei;Xin'an Wu(Department of Pharmacy,the First Hospital of Lanzhou University,Lanzhou 730000,China;College of Pharmaceutical Sience,Lanzhou University,Lanzhou 730000,China)
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2018年第7期498-509,共12页 中国药学(英文版)
基金 The National Natural Science Foundation of China(Grant No.81373494 and 81041086) Tianqing Liver Disease Rearch Fund(Grant No.TQGB20180088)
关键词 对乙酰氨基酚 肝损伤 胆酸盐 肝组织转运体 Acetaminophen Hepatotoxicity Bile acids Hepatobiliary transporter
  • 相关文献

参考文献1

二级参考文献15

  • 1Thomas Pusi,Ulrich Beuers.Ursodeoxycholic acid treatment of vanishing bile duct syndromes[J].World Journal of Gastroenterology,2006,12(22):3487-3495. 被引量:18
  • 2Daisuke Komichi,Susumu Tazuma,Tomoji Nishioka,Hideyuki Hyogo,Mizuho Une,Kazuaki Chayama.Unique Inhibition of Bile Salt-Induced Apoptosis by Lecithins and Cytoprotective Bile Salts in Immortalized Mouse Cholangiocytes[J].Digestive Diseases and Sciences.2003(12)
  • 3Seon-Hee Oh,Ki-Jung Yun,Ji-Xing Nan,Dong-Hwan Sohn,Byung-Hoon Lee.Changes in expression and immunolocalization of protein associated with toxic bile salts-induced apoptosis in rat hepatocytes[J].Archives of Toxicology.2003(2)
  • 4Predrag Ljubuncic,Zahava Tanne,Arieh Bomzon.Ursodeoxycholic Acid Suppresses Extent of Lipid Peroxidation in Diseased Liver in Experimental Cholestatic Liver Disease[J].Digestive Diseases and Sciences.2000(10)
  • 5Ermenegildo E. Frezza,Giorgio E. Gerunda,Mario Plebani,Alessandra Galligioni,Alda Giacomini,Daniele Neri,Alvise Maffei Faccioli,Dr. Claudio Tiribelli.Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat[J].Digestive Diseases and Sciences.1993(7)
  • 6Calmus Y,Guechot J,Podevin P,Bonnef is MT,Giboudeau J,Poupon R.Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes[].Hepatology.1992
  • 7Yoshikawa M,Matsui Y,Kawamoto H,Toyohara M,Matsumura K,Yamao J,Kuriyama S,Fukui H,Ishizaka S.Intragastric administration of ursodeoxycholic acid suppresses immunoglobulin secretion by lymphocytes from liver, but not from peripheral blood, spleen or Peyer‘s patches in mice[].International Journal of Immunopharmacology.1998
  • 8Tanaka H,Makino Y,Miura T,Hirano F,Okamoto K,Komura K,Sato Y,Makino I.Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway[].J Immunol.1996
  • 9Oftebro H,Bjorkhem I,Strmer FC,Pedersen JI.Cerebrotendinous xanthomatosis: defective liver mitochondrial hydroxylation of chenodeoxycholic acid precursors[].Journal of Lipid Research.1981
  • 10Thomas C,Pellicciari R,Pruzanski M,Auwerx J,Schoonjans K.Targeting bile-acid signalling for metabolic diseases[].Nature Reviews Drug Discovery.2008

共引文献55

同被引文献4

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部